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• The cardiovascular risk conferred by lipoprotein(a) is determined by the lipoprotein(a) serum concentration.• Serum lipoprotein(a) levels should be measured in five specific population groups.• Recommendations on the management of patients with raised lipoprotein(a) levels (> 90 nmol/l) are discussed.
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A B S T R A C T
Lipoprotein(a), Lp(a), is a modified atherogenic low-density lipoprotein particle that contains apolipoprotein(a).
Its levels are highly heritable and variable in the population. This consensus statement by HEART UK is based on
the evidence that Lp(a) is an independent cardiovascular disease (CVD) risk factor, provides recommendations
for its measurement in clinical practice and reviews current and emerging therapeutic strategies to reduce CVD
risk. Ten statements summarise the most salient points for practitioners and patients with high Lp(a).
HEART UK recommends that Lp(a) is measured in adults as follows: 1) those with a personal or family history
of premature atherosclerotic CVD; 2) those with first-degree relatives who have Lp(a) levels> 200 nmol/l; 3)
patients with familial hypercholesterolemia; 4) patients with calcific aortic valve stenosis and 5) those with
borderline (but< 15%) 10-year risk of a cardiovascular event. The management of patients with raised Lp(a)
levels should include: 1) reducing overall atherosclerotic risk; 2) controlling dyslipidemia with a desirable non-
HDL-cholesterol level of< 100mg/dl (2.5 mmol/l) and 3) consideration of lipoprotein apheresis.
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1. Background
Although Lipoprotein(a) (Lp(a)) is now established as a causal risk
factor for cardiovascular disease (CVD) [1–3], there is little consensus
between the different national guidelines on how to use this informa-
tion on Lp(a) to more accurately estimate and modify cardiovascular
risk [4,5]. For instance, the 2012 Australian Guideline does not mention
Lp(a) [6]. On the other hand, the 2019 European Guideline on CVD
prevention in clinical practice suggests measuring Lp(a) at least once in
each adult person's lifetime7. The 2016 Canadian Cardiovascular So-
ciety Guideline also adopts a similar approach [8]. The 2018 American
College of Cardiology/American Heart Association Guideline on blood
cholesterol defined Lp(a) as a ‘risk-enhancing factor’, especially at
higher levels of Lp(a) [9]. In part these differences in national state-
ments reflect, as acknowledged by the National Heart, Lung and Blood
Institute's Lp(a) working group, gaps in our knowledge of how Lp(a)
mechanistically contributes to CVD and calcific aortic valve disease
(CAVD) [10].
The importance of reducing Lp(a) associated cardiovascular risk
requires a reappraisal for four main reasons: 1) genetic studies have
demonstrated an unequivocal strong link between genes associated
with increased Lp(a) and cardiovascular risk [3,11,12] and as well as
the protective effect of LPA null alleles or other strongly Lp(a)-de-
creasing alleles and CVD risk [13,14]; 2) new insights into Lp(a) assay
methodology suggest that inaccurate quantitation of Lp(a) has led
historically to its underestimation as a cardiovascular risk factor
[10,15]; 3) Lp(a) contributes to aortic valve calcification [16–18] and
4) the emergence of effective therapies for reducing Lp(a) levels [19]. In
this statement we advocate more widespread clinical use of Lp(a) data
to refine assessment of cardiovascular risk (Table 1) based on its ac-
curate and reliable measurement.
Lp(a) is a LDL-like particle, with a single apolipoprotein B100
(apoB), covalently linked by a disulphide bond to a single apolipopro-
tein(a) (apo(a)) (Fig. 1). The molecular mass of apo(a) can vary be-
tween 275 and 800 kDa [20,21] due to the inheritance of> 40 different
allelic LPA variants encoding different numbers of kringle IV type 2
repeat sequences in this polypeptide [22]. The rate of apo(a) synthesis
and secretion is inversely related to its molecular mass, and conse-
quently, individuals who produce the lower molecular mass apo(a)
isoforms have higher serum Lp(a) levels than those who produce the
higher molecular mass isoforms [21,23,24]. Indeed, this explains the
results of early genetic studies which established that serum Lp(a) levels
are predominantly genetically inherited in an autosomal co-dominant
manner [20,21,25] and that allelic variation at the LPA locus is largely
responsible for the wide, potentially as much as 1000-fold differences in
serum Lp(a) levels [12,26,27].
2. Epidemiology
It is now well-established that serum Lp(a) concentrations and their
distribution vary with ethnicity and local population structures. The
apo(a)-size allele affects serum Lp(a) concentrations to different de-
grees in different populations, with one study reporting that the var-
iation in KIV-2 repeat number accounted for 63.2% of the total varia-
bility in Lp(a) levels in Caucasians and just 38.6% in African Blacks
[28]. In Caucasians, 80% of the population have a serum Lp
(a) < 90 nmol/l (40mg/dl) and the distribution is positively skewed
[12], however, people of African descent have levels twice as high as
Caucasians, Hispanics and certain Asian populations, whereas South
Asians have intermediate levels [1,29–32]. No sex-specific differences
in distributions of Lp(a) levels have previously been noted [33]. How-
ever, recent large studies have suggested that women have slightly
higher levels than men [34–36].
Historically, progress in establishing the contribution of Lp(a) in
CVD pathogenesis has been compromised by lack of standardised
methods for measuring serum levels of this atherogenic lipoprotein (see
Table 1
Ten statements on Lipoprotein(a) from HEART UK.
1. Lipoprotein(a) is an independent risk factor for cardiovascular disease and calcific
aortic valve stenosis.
2. The cardiovascular risk conferred by lipoprotein(a) is determined by the
lipoprotein(a) serum concentration: 32–90 nmol/l minor; 90–200 nmol/l
moderate; 200–400 nmol/l high; > 400 nmol/l very high.
3. Lipoprotein(a) levels are genetically determined with an autosomal co-dominant
inheritance.
4. Secondary causes of high lipoprotein(a) should be sought and, if possible,
corrected.
5. Regarding measurement:
a) Serum Lipoprotein(a) concentrations should be measured using a method where
the effect of isoform size has been minimized using appropriate antibodies with
calibrators certified for traceability of Lp(a) values to the WHO/IFCC reference
material.
b) Results should be expressed in nmol/l of Lp(a) particles.
c) Conversion of mass units to molar units or vice versa introduces inaccuracy and
should be discouraged.
d) Currently only assays based on Denka reagents with calibrators traceable in
nmol/L to WHO/IFCC reference material can be recommended.
6. Lipoprotein(a) levels need only be measured once, unless a secondary cause is
suspected or specific treatment is instituted in order to lower levels.
7. Serum Lipoprotein(a) levels should be measured in those with:
a) a personal or family history of premature atherosclerotic cardiovascular disease
(< 60 years of age)
b) first degree relatives with raised serum Lp(a) levels (> 200 nmol/l)
c) familial hypercholesterolemia (FH), or other genetic dyslipidemias
d) calcific aortic valve stenosis
e) a borderline increased (but <15%) 10-year risk of a cardiovascular event
8. The management of patients with raised lipoprotein(a) levels (> 90 nmol/l)
should include:
a) reducing overall atherosclerotic risk
b) controlling hyperlipidemia
c) consideration of lipoprotein apheresis as per the HEART UK Lipoprotein
apheresis statement [58].
9. In patients with raised Lipoprotein(a) levels (> 90 nmol/l), desirable non-HDL-
cholesterol is < 100mg/dl (2.5mmol/l).
10. Future work needs to focus on:
a) Development of commercial truly isoform insensitive assays
b) randomised, controlled interventional studies that selectively lower Lipoprotein
(a) in primary and secondary prevention of ASCVD
c) the role of antiplatelet therapy in primary prevention
d) Lipoprotein(a) reference ranges in different ethnic groups
*The 2016 ACC/AHA Clinical Guideline Recommendation Classification System
has been followed to assess strength of recommendation and guide the phrasing
of the recommendation.
Fig. 1. The structure of Lipoprotein(a).
The Lp(a) particle contains a single molecule of apo(a) and the 4536 amino acid
apoB100 polypeptide (blue ribbon), which forms a ribbon and bow-like struc-
ture around the cholesteryl-ester core of the LDL component of this particle.
Apo(a) contains 10 classes (coloured balls) of kringle modules, designated KIV-
1-10, KV and a protease domain. The variable number of KIV-2 modules forms
the basis of the observed isoform size heterogeneity of apo(a), which may im-
pact on the non-covalent interactions between this molecule and apoB. There is
a disulphide bond formed between a free cysteine in KIV-9 and the apoB100
cysteine 4326.
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Measurement of Lp(a) section below), with the consensus being that
estimates based on these data underestimated the importance of Lp(a)
as a cardiovascular risk factor [15]. In 2003, WHO accepted protocols
for standardisation of Lp(a) assays, which now allows its more reliable
quantification. Although there remain large differences between assays,
these protocols have reduced the bias caused by isoform size of Lp(a)
and have made within study comparisons more robust [15]. Hence, in
the past decade there has been consolidation of the evidence that ele-
vated serum Lp(a) is a risk factor for coronary heart disease (CHD),
ischaemic stroke, peripheral artery disease, as well as calcific aortic
valve stenosis [11,12,37,38]. Moreover, Mendelian randomisation stu-
dies and genome wide association studies support Lp(a) as an in-
dependent cardiovascular risk factor12 11. Thus, the principles behind
current methodologies and the inherent difficulties in fully capturing
the unique lipid and structural properties of Lp(a) particles (Fig. 1) are
discussed in the context of our Statement 5.
In 2009, the Emerging Risk Factors Collaboration (ERFC) published
a meta-analysis of 39 long-term prospective studies, that comprised a
total of 126,634 individuals (1.3 million person-years of follow-up)
with recorded baseline serum Lp(a) concentration and subsequent
major vascular morbidity and/or mortality data [38]. Serum Lp(a) le-
vels were consistent within individuals over a period of several years.
The risk ratio for CHD, adjusted for age and sex, was 1·16 (95% CI, 1·11-
1·22) per 3·5-fold higher usual Lp(a) levels (ie, per 1 SD), and 1·13 (95%
CI, 1·09-1·18) after further adjustment for traditional risk factors. The
corresponding adjusted risk ratios were 1·10 (95% CI, 1·02-1·18) for
ischemic stroke, 1·00 (95% CI, 0·97-1·04) for cancer deaths, and 1·00
(95% CI, 0·95-1·06) for nonvascular deaths other than cancer. Thus,
there was a continuous and independent association of serum Lp(a)
concentration with risk of CHD and stroke. Moreover, it is likely that
published meta-analyses of Lp(a)-conferred risk, such as the ERFC, have
underestimated Lp(a)-conferred risk due to the incorporation of studies
using isoform biased assays.
Lp(a) is also a potent risk factor for calcific aortic valve stenosis
[16,37]. Data from the ASTRONOMER trial, which included patients
with mild-moderate aortic stenosis, found that patients with the highest
levels of Lp(a) (>~150 nmol/l (> 58.5mg/dl)) had a greater rate of
disease progression and need for earlier valve replacement [17].
3. Genetics and secondary causes of elevated Lp(a)
The epidemiological findings from the ERFC [38] that elevated Lp
(a) levels constitute a major independent risk factor for CHD and stroke
are corroborated by the results of genetic studies which provide evi-
dence that LPA-Lp(a) raising variants increase CHD [39]. In 2009,
Kamstrup et al. published a Mendelian randomisation study involving
40,000 participants from the Copenhagen City Heart Study (CCHS), the
Copenhagen Ischaemic Heart Disease Study (CIHDS) and Copenhagen
General Population Study (CGPS) [12]. In all three cohorts, there was
strong association between plasma Lp(a) levels and the LPA kringle IV
type 2 (KIV-2) copy number variation (calculated as the sum of KIV-2
repeats of the two alleles); for example, in the CGPS contingent, this
size variation explained ~27% of the variance in Lp(a) levels. More-
over, a lower KIV-2 copy number, and hence higher Lp(a) concentra-
tion, was associated with a significantly higher risk of myocardial in-
farction (MI) in this study. In particular, an Lp(a) level > 95th
percentile had a 3- to 4-fold increase in multi-factorial-adjusted risk of
MI and absolute 10-year risks of 20% and 35% in high risk women and
men [40]. Conversely, individuals with a common null LPA allele, and
consequently low Lp(a) levels, had reduced CVD risk (odds ratio, 0.79
(95% CI 0.66–0.97)) compared with non-carriers, providing further
support for a causal role of Lp(a) in CVD [41].
Besides the KIV-2 copy number variation, two LPA single nucleotide
polymorphisms (SNP) were found by a candidate gene association study
to display association with higher serum Lp(a) levels and increased
CHD risk [11]. In outline, SNP rs10455872 and rs3798220 accounted
for 25% and 8% of the variation in serum Lp(a) levels, respectively.
Similarly, a subsequent larger-scale genome wide association study,
involving 63,746 individuals with CHD and 130,681 controls, showed
that the loci most strongly associated with CHD were in the LPA region
and not in other loci that are well known to be associated with in-
creased CHD risk, such as LDL-R and PCSK-9 [42].
Although Lp(a) concentrations are predominantly (70 to>90%)
under genetic control [25], some non-genetic factors are known to in-
fluence it. In chronic kidney disease, serum Lp(a) concentrations rise
with falling glomerular filtration rate due to reduced catabolism of the
larger isoforms [43]. Renal transplantation appears effective at re-
turning Lp(a) concentration to baseline [29]. Serum Lp(a) levels are
fourfold higher in individuals with nephrotic range proteinuria than
controls and this appears to be due to increased rates of Lp(a) synthesis
across all isoform sizes although reduced catabolism may also play a
role [29]. Lp(a) levels are reduced in most forms of liver disease but
show weak, positive association with biomarkers of inflammation [29].
Serum Lp(a) levels, which are increased in patients with overt hy-
pothyroidism, are reduced by levothyroxine replacement, but in sub-
clinical hypothyroidism do not change significantly [44]. Serum Lp(a)
levels are not consistently associated with age or gender but levels are
significantly reduced by hormone replacement in postmenopausal
women [45]. Thus, secondary causes of high Lp(a) such as chronic
kidney disease, nephrotic syndrome and hypothyroidism should be
sought and corrected.
4. Pathogenicity
Lp(a) promotes atherosclerosis by two principal mechanisms
[46,47]. As an LDL-like particle, Lp(a) can infiltrate into the arterial
intima and bind components of the extracellular matrix, enhancing
macrophage infiltration and smooth muscle proliferation [48]. Within
the atherosclerotic plaque of coronary lesions and carotid en-
darterectomy specimens, a substantial proportion of circulating oxi-
dised phospholipids reside on Lp(a). These oxidised phospholipids are
implicated in driving monocyte trafficking into the arterial wall and
enhancing pro-inflammatory cytokine release [47]. Secondly, through
its similarity to plasminogen, Lp(a) is envisaged to have a pro-
thrombotic effect by inhibiting fibrinolysis. Apo(a) may also promote
platelet aggregation by mediating the binding of Lp(a) to plasminogen
receptors on the platelet surface and granule release via the thrombin
receptor. Some biochemical studies have also demonstrated anti-fi-
brinolytic effects of Lp(a) [46].
4.1. Lp(a)-associated risk
The risk conferred by serum Lp(a) depends on its serum con-
centrations, those with most severely elevated Lp(a) being at greatest
risk of CVD [12]. We propose that the graded impact of elevated serum
Lp(a) concentrations on this risk be classified as follows: 32–90 nmol/l
minor; 90–200 nmol/l moderate; 200–400 nmol/l high;> 400 nmol/l
very high (Table 2). These cut-offs expressed in molar units are derived
from population percentiles of Lp(a) measured in nmol/l and mg/dl
from 13,900 participants (Nov. 2015 to June 2017) in the on-going
Copenhagen General Population Study, described above [12]. Mea-
surements were performed with the Roche assay on a Cobas platform
calibrated in nmol/l (unpublished data, courtesy of P. Kamstrup and B.
Nordestgaard). It must be noted that this dataset derives predominantly
from Danish Caucasian populations and further work on establishing
clinically relevant Lp(a) cut-off values in a range of ethnicities is still
warranted (discussed in ‘Further Work’). Recognising the importance of
elevated Lp(a), in October 2018 the Center for Disease Control and
Prevention instituted two ICD-10 codes for diagnosis of elevated Lp(a).
Statement 1. Lipoprotein(a) is an independent risk factor for CVD and
calcific aortic valve stenosis.
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Statement 2. The CV risk conferred by Lp(a) is determined by the Lp(a)
serum concentration: 32–90 nmol/l minor; 90–200 nmol/l moderate;
200–400 nmol/l high;> 400 nmol/l very high.
Statement 3. Lipoprotein(a) levels are genetically determined with an
autosomal co-dominant inheritance.
Statement 4. Secondary causes of high lipoprotein(a) should be sought
and, if possible, corrected.
5. Measurement of Lp(a) and challenges
Lp(a) expressed in mass units (mg/dl) encompasses the mass of the
entire particle; this comprises apo(a), apoB-100, cholesterol, cholesteryl
esters, phospholipids and triglycerides. Because of the heterogeneity in
apo(a) size and the presence in most individuals of two different, ge-
netically determined apo(a) isoform sizes, standardisation using a
single calibrant material is impossible.
Furthermore, variable numbers of repeated KIV-2 units in Lp(a) act
as multiple epitopes in immunoassays. Unless calibrants have the same
range of isoforms as test samples, serum levels of Lp(a) in those with
higher numbers of KIV-2 repeats will be overestimated and those with
smaller numbers underestimated. As smaller isoforms are strongly as-
sociated with higher serum concentrations, there will be greater un-
derestimation of Lp(a) at higher concentration than at lower ones. This
leads to an under-estimation of Lp(a) associated CVD risk: it is very
unlikely to be overestimated [15,49]. Furthermore, there is some evi-
dence that smaller isoforms are more atherogenic [2] and so this effect
could be exacerbated.
No available commercial immunoassays employ isoform insensitive
antibodies. The gold standard method at the moment is the Northwest
Lipid Metabolism and Diabetes Research Laboratory (NLMDRL) method
that uses an isoform insensitive antibody and is meticulously calibrated
with well characterized material, however this assay is not commer-
cially available. Transferring values using this method to WHO/IFCC-
verified reference material and calibrators have made assay measure-
ments more uniform. Assays using Denka reagents are the most reliable
commercial assays available. There are several explanations for this.
The effect of isoform size has been reduced by use of a range of cali-
brators prepared from separate pools of serum covering a range of Lp(a)
concentrations. As concentration and isoform size are inversely corre-
lated this better matches calibrants with test samples. Even so, molar
mass ratios have been shown to increase with increasing molar con-
centration of Lp(a) measured by the NLMDRL assay. Again as isoform
size and molar concentration are inversely correlated the mass per
particle at higher concentrations will be less. Over estimation of larger
isoforms will have the same effect and be more prominent at lower
concentration. A further source of variability in molar mass ratio is the
assignment of values in mass units to commercial calibrators. Because
test samples contain a mixture of isoforms of Lp(a) it is impossible to
convert mass units to molar units without detailed knowledge of the
isoform composition. This problem is obviated by manufacturing ma-
terials calibrated in molar units traceable to WHO/IFCC verified re-
ference materials in molar units. Methods based on Denka reagents
calibrated in nmol/L and traceable to WHO/IFCC reference material
have acceptable bias compared with the NLMDRL gold standard
method [15].
Statement 5. Regarding the measurement of Lp(a):
a. Serum Lipoprotein(a) concentrations should be measured using a
method where the effect of isoform size has been minimized using
appropriate antibodies with calibrators certified for traceability of
Lp(a) values to the WHO/IFCC reference material.
b. Results should be expressed in nmol/l of Lp(a) particles.
c. Conversion of mass units to molar units or vice versa introduces
inaccuracy and should be discouraged.
d. Currently only assays based on Denka reagents with calibrators
traceable in nmol/L to WHO/IFCC reference material can be re-
commended.
6. In whom should Lipoprotein(a) levels be measured?
Serum Lp(a) levels remain relatively stable over a lifespan [29]
because they are predominantly genetically determined. Measuring
serum Lp(a) concentrations as a proxy for its genetic determinants is
practical and more cost effective than genetic testing at the current
time. To improve the accuracy of cardiovascular risk assessment a
single measurement of serum Lp(a) is sufficient for most patients. Al-
though we have indicated broad ranges of Lp(a) concentrations asso-
ciated with increasing cardiovascular risk, clinical judgement needs to
be exercised for values at the cut-points. The overall precision of repeat
measurement in an individual should be sufficient to base decisions on
a single measurement, however, qualification of levels that are close to
action thresholds should to be considered on a case-by-case basis. Re-
peat measurement is only indicated if a secondary cause is suspected or
therapeutic measures to lower levels have been instigated.
Our recommendation for once-only measurement of Lp(a) is con-
sistent with the recently published European guideline [7], however,
we recommend that Lp(a) is only measured in specific cohorts (see
following paragraphs) rather than in all adults. Population screening of
Lp(a) is not currently advocated by the HEART UK consensus panel. The
European guideline aims to identify those with very high Lp(a)
(> 430 nmol/L). In contrast, we argue that the risk conferred by Lp(a)
occurs at a much lower Lp(a) threshold than this. Therefore, our ap-
proach is to measure Lp(a) in targeted populations and manage Lp(a)-
associated risk in those with levels> 90 nmol/l.
In patients with a family history of premature CVD (< 60 years),
particularly when a causative mutation for Familial
Hypercholesterolemia (FH) has not been identified, a knowledge of
their Lp(a) value may help both the patient and physician to understand
the basis of the familial CV risk. This improved understanding may also
influence an individual's decision to start and adhere to long-term
medication.
A role for formal family cascade testing for raised serum Lp(a) has
not yet been established. However, given the dominant inheritance of
Lp(a) levels, the testing of family members of index cases with severely
raised levels (> 200 nmol/l) may be useful. Genetic testing for SNPs
associated with serum Lp(a) levels is not currently advocated in routine
clinical practice.
Patients with heterozygous FH (HeFH) have higher levels of serum
Table 2
The cardiovascular risk conferred by lipoprotein(a) is graded dependent on the
lipoprotein(a) level.
Lp(a) level nmol/la Lp(a) level
approx. in mg/
dlb
Percentile of general
population [12]
Impact on CV
risk
32–90 18–40 67–80th Minor
90–200 40–90 80–95th Moderate
200–400 90–180 95–99.8th High
> 400 >180 >99.8th Very High
a Percentile cutpoints in nmol/l and mg/dl for Lp(a) values derived from
13,900 participants (Nov. 2015 to June 2017) in the on-going Copenhagen
General Population Study. Measurements were performed with the Roche assay
on a Cobas platform (unpublished data, courtesy of P. Kamstrup and B.
Nordestgaard).
b The factor to convert Lp(a) values from nanomoles per liter of apo(a) to
milligrams per deciliter is for guidance only and should not be applied to data
generated with other methods because it is assay specific [86] and dependent
on: 1) the size of apo(a) in the samples and 2) how the target values in mg/dl
were assigned to the assay calibrators.
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Lp(a) compared to their non-affected siblings [50]. Lp(a) is a strong risk
factor for CHD in patients with HeFH, independent of age, sex, smoking
status, and serum LDL-C levels [51,52]. Thus, knowledge of a FH pa-
tient's Lp(a) levels would inform the physician further regarding the
patient's risk of a CVD event and on the potential benefits of a more
aggressive approach to manage their hyperlipidaemia and any other
unaddressed CVD risk factors [53]. Serum Lp(a) is not a predictor of
CHD in homozygous FH patients on currently available cholesterol-
lowering treatment, but may become so when lower levels of LDL-C are
achieved [54]. On this basis, it is recommended that Lp(a) levels should
be measured in those with familial hypercholesterolemia and other
genetic dyslipidemias (including familial combined hyperlipidaemia,
familial dysbetalipoproteinaemia, and familial hypertriglyceridaemia)
which also increase CV risk.
Lp(a) is a potent risk factor for calcific aortic valve stenosis [16,37].
The knowledge of a patient's Lp(a) levels could inform selection of the
interval for valve surveillance of those with established aortic valve
disease as patients with raised Lp(a) are likely to require earlier inter-
vention.
Lp(a) best re-classifies CVD risk in people at intermediate risk [55].
Patients with>15% risk of a CV event over 10 years should be re-
ceiving treatment such as statin therapy irrespective of Lp(a) level. In
the UK, uptake of statin therapy for primary prevention of CVD in pa-
tients of intermediate risk is poor, with only 14% of patients with a 10
year CV risk of between 10 and 19.9% initiated on a statin in one study
[56]. The addition of serum Lp(a) measurement, at least up to the mid-
point of this range, would aid reclassification of people at intermediate
risk and could encourage initiation and acceptance of LDL-C-lowering
therapies.
Statement 6. Lipoprotein(a) levels need only be measured once, unless
a secondary cause is suspected or specific treatment is instituted in
order to lower levels.
Statement 7. Serum Lipoprotein(a) levels should be measured in those
with:
a. A personal or family history of premature atherosclerotic cardio-
vascular disease (< 60 years of age)
b. First degree relatives with raised serum Lp(a) levels (> 200 nmol/l)
c. Familial hypercholesterolemia (FH), or other genetic dyslipidemias
d. Calcific aortic valve stenosis
e. A borderline increased (but< 15%) 10-year risk of a cardiovascular
event
7. Management of patients with raised Lipoprotein(a)
A major challenge in establishing the role of Lp(a) as an important
cardiovascular risk factor has been the lack of effective treatments to
reduce Lp(a) levels. As a consequence, there is a paucity of evidence
that decreasing serum Lp(a) levels reduces cardiovascular risk and
clinical outcome trials of specific Lp(a)-lowering therapies are eagerly
awaited. In the last 5 years, several novel lipid-lowering agents that can
lower Lp(a) have emerged but of these, only two monoclonal antibody
PCSK-9 inhibitors have been licensed for general use. Furthermore,
Mendelian randomisation studies suggest a large absolute reduction in
Lp(a) may be required to produce clinically meaningful reduction in CV
risk [3,57]. The various therapeutic strategies for management of pa-
tients with raised Lp(a) are outlined here and summarised in Table 3.
Our current recommendation for managing patients, in both primary
and secondary prevention, with raised Lp(a) levels (> 90 nmol/l) in-
cludes: 1) reducing overall atherosclerotic risk 2) controlling dyslipi-
demia and 3) consideration of lipoprotein apheresis as per the HEART
UK Lipoprotein apheresis statement [58].
Reducing CVD risk and controlling dyslipidaemia. This pragmatic ap-
proach does not directly target Lp(a) levels but addresses dyslipidemia
and other modifiable CVD risk factors, such as blood pressure and
smoking with the aim of mitigating the risk conferred by Lp(a). In the
EPIC-Norfolk study, patients with raised Lp(a) with the healthiest car-
diovascular health score (including body mass index, healthy diet,
physical activity, smoking status, blood pressure, diabetes and choles-
terol levels) had substantially reduced CVD risk compared to partici-
pants in the unhealthiest cardiovascular health score category. This
highlights the importance of maintaining a healthy lifestyle for patients
with raised Lp(a) [59]. Aggressive LDL-C lowering can mitigate the
CVD risk conferred by Lp(a) [60,61]. However, studies such as AIM-
HIGH suggest that even at low LDL-C (or low non-HDL-C levels), pa-
tients with high Lp(a) fare worse than their counterparts with low Lp(a)
levels [62] implying incomplete elimination of the risk conferred by
elevated Lp(a) levels. Similarly, Wei et al. [63] have recently demon-
strated persistence of the association between LPA genetic variants and
CVD events in individuals with LDL-C≤ 70mg/dl who were taking
statins. A meta-analysis of statin-treated patients with elevated lipo-
protein(a) also showed an association with cardiovascular disease risk
[64]. Recent work suggests that statins may actually modestly increase
Lp(a) levels, possibly by increasing Apo(a) expression, however, this
requires further study [65].
Apheresis. The HEART UK Lipoprotein apheresis guidelines re-
commend that apheresis should be considered for those patients with
progressive coronary disease and Lp(a) greater than ~150 nmol/l
(> 60mg/dl) whose LDL-C remains 125mg/dl (3.3mmol/l) despite
maximal lipid-lowering therapy [58]. In Germany, Lp(a) levels ex-
ceeding ~150 nmol/l (60mg/dl) along with progressive CVD (regard-
less of LDL-C levels) has been approved as an indication for regular
lipoprotein apheresis since 2008. Studies on such patients undergoing
regular apheresis suggest a reduction in cardiovascular risk [66–68].
Unfortunately, studies to date using lipoprotein apheresis have not in-
cluded a simultaneous control group, therefore, it is difficult to estimate
the magnitude of benefit. Lipoprotein apheresis was recently employed
in patients with refractory angina and raised Lp(a) in a randomised,
controlled, cross-over trial and found to improve myocardial perfusion,
atheroma burden and exercise capacity [69]. Thus, although apheresis
may be of cardiovascular benefit in those with raised Lp(a), access to
this form of treatment is currently limited by cost and few centres are
able to offer it.
The following interventions for the management of Lp(a) are NOT
currently recommended by the group, however, the evidence for their
use (or lack of) is summarised below:
Niacin. Until recently, niacin was used to treat high Lp(a) levels,
reducing levels by 30–40% [70]. However, the use of niacin is not
supported by HEART UK based on AIM-HIGH [71] and HPS2-THRIVE
[72] trial findings. Niacin increased the risk of serious adverse events
and did not reduce the risk of a major vascular event, leading to its
withdrawal by the European Medicines Agency (EMA) in 2013.
Aspirin. Aspirin is used in clinical practice to counter the pro-
thrombotic risk conferred by Lp(a). However, the efficacy of this has
not been tested prospectively. In the Women's Health Study, carriers of
an LPA variant associated with elevated Lp(a) levels had a doubling of
cardiovascular risk and appeared, on retrospective analysis, to benefit
more from aspirin than non-carriers [73]. Two recent randomised
controlled trials on the use of aspirin in primary prevention, one in-
volving patients with moderate cardiovascular risk [74] and the other
in an elderly population [75], failed to show a favorable benefit:risk
ratio although a sub-group analysis stratified by Lp(a) levels remains to
be performed. Further prospective studies investigating the effect of
aspirin in patients with elevated Lp(a) are warranted. Aspirin may also
reduce Lp(a) levels by reducing apo(a) expression [76] although the
evidence for this has come from very small studies [77] and requires
confirmation.
Licensed novel agents. Monoclonal antibodies to proprotein con-
vertase subtilisin/kexin type 9 (PCSK9), such as evolocumab and alir-
ocumab, can reduce Lp(a) concentrations by 20–30% [78]. In
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exploratory analyses in clinical trials, CV event risk reduction appeared
greater in treated subjects with higher Lp(a), but these agents are not
currently licensed for lowering Lp(a) [79,80]. It is uncertain as to how
much of the absolute risk reduction attributable to PCSK9 inhibition,
which is higher in patients with high Lp(a), is explained by Lp(a) re-
duction or simply due to LDL-C lowering, given that patients with high
Lp(a) levels are at higher absolute risk of CVD.
Novel agents in development. Antisense oligonucleotides targeting
hepatic LPA RNA reduce apo(a) production and Lp(a) assembly with
apoB. Three clinical trials using this antisense therapy have now been
reported [19,81]. In the first, involving patients who had baseline Lp(a)
levels of 125–437 nmol/L, IONIS-APO(a)Rx reduced mean Lp(a) re-
ductions by 66·8% (SD 20·6). In the second cohort of patients, with Lp
(a) ≥438 nmol/l, there was a 71·6% reduction at 12 weeks.
A recent advance in antisense technology has led to the develop-
ment of IONIS-APO(a)-LRx, a ligand-conjugated antisense oligonucleo-
tide designed to be highly and selectively taken up by hepatocytes. In a
phase 1/2a first-in-man study, this molecule achieved a mean reduction
in serum Lp(a) of 92% at 36 days. A phase 2 clinical trial in patients
with Lp(a)≥~150 nmol/l (60mg/dl) and established CVD completed
in November 2018 (NCT03070782). An siRNA-based therapy targeting
LPA RNA is also in early development phase (NCT03626662).
Statement 8. The management of patients with raised lipoprotein(a)
levels (> 90 nmol/l) should include:
a. Reducing overall atherosclerotic risk
b. Controlling hyperlipidemia
c. Consideration of lipoprotein apheresis as per the HEART UK
Lipoprotein apheresis statement [58].
8. Targets
In patients with raised Lp(a), standard algorithms used in risk cal-
culators such as the ACC/AHA Pooled Cohort Equations [82], Systemic
Coronary Risk Evaluation (SCORE) [7] and QRISK®3–2017 [83] may
underestimate cardiovascular risk. In the absence of randomised, con-
trolled trial data demonstrating reduced CV risk with reduction in Lp
(a), it is not possible to suggest a desirable target for Lp(a). Instead, in
patients with a raised serum Lp(a) > 90 nmol/l, we recommend mul-
tiple risk factor intervention to reduce atherosclerotic risk. This should
include achievement of greater than 50% reduction in non-HDL-C as
the priority to reduce cardiovascular risk, with high intensity statins as
the first line medication. The alternative, absolute non-HDL-C target
of< 100mg/dl (2.5mmol/l) as recommended by JBS3 [84] is ap-
proximately equivalent to LDL-cholesterol< 70mg/dl (1.8 mmol/l) as
per the 2016 ESC/EAS guideline [7]. In patients with progressive CVD
and a history of recurrent events despite maximum tolerated lipid
lowering therapy, including PCSK9 inhibitors, consideration should be
given to lipoprotein apheresis if Lp(a) is above 150 nmol/l.
Although both LDL-C (and non-HDL-C) measurements contain a
contribution from Lp(a) cholesterol which could potentially lead to
overestimation of LDL-C, correction factors for non-HDL-C and LDL-C to
exclude Lp(a) associated cholesterol are 1) not validated with isoform
independent assays in treated and untreated patients 2) not validated in
large epidemiological studies for CV risk prediction or in RCTs of lipid
lowering therapies and 3) not in clinical use. Therefore, correction for
Lp(a) cholesterol is not currently recommended. Nevertheless, it should
be recognized, that the contribution of Lp(a) to LDL-C and non-HDL-C
may be substantial. Expression of Lp(a) in molar units allows appre-
ciation of its concentration relative to apo B expressed in molar units.
Statement 9. In patients with raised Lipoprotein(a) levels (>90 nmol/l),
desirable non-HDL-cholesterol is < 100mg/dl (2.5mmol/l).
9. Future research
Commercial assays for Lp(a) do not use antibodies that are isoform
independent. The development of such an antibody on a commercial
scale would considerably improve consistency between assays. The
National Heart, Lung, and Blood Institute have recently published re-
commendations to facilitate basic, preclinical and clinical research on
Lp(a) [10]. In our opinion, research evidence is required in three key
areas in order to guide the management of Lp(a) associated CV risk.
Firstly, interventions that can selectively lower Lp(a), such as Lp(a)
apheresis and antisense oligonucleotides to LPA RNA, should be tested
in randomised, controlled clinical trials to evaluate their effect on CVD
outcomes. These should be performed for both primary and secondary
prevention, as well as in specific disease states, such as FH and calcific
aortic valve stenosis. Clinical trials in secondary prevention should be a
priority and if successful, will allow health economic analysis to be
performed. The inclusion criterion threshold level of Lp(a) in these
outcome studies will need to be carefully chosen, possibly around
~150 nmol/l, the current threshold for apheresis in Germany [85].
Second, the role of antiplatelet therapy for primary prevention in pa-
tients with elevated Lp(a) needs to be clarified in prospective rando-
mised, controlled clinical trials. Finally, studies in global multi-ethnic
populations have highlighted pronounced differences in Lp(a) levels
across ethnicities. Ethnicity is a key variable in assigning cut-off values
of Lp(a) for cardiovascular risk prediction. Further epidemiological
studies of specific ethnic groups are required to establish clinically re-
levant Lp(a) cut-off values.
Statement 10. Future work needs to focus on:
a. Development of commercial truly isoform insensitive assays
b. Randomised, controlled interventional studies that selectively lower
Lipoprotein(a) in primary and secondary prevention of ASCVD
c. The role of antiplatelet therapy in primary prevention in patients
with elevated Lipoprotein(a)
d. Lipoprotein(a) reference ranges in different ethnic groups.
Search strategy and selection criteria
Data for this Review were identified by searches of Web of Science,
PubMed, and references from relevant articles using the search terms
“Lipoprotein(a)”, “Lp(a)”, and “cardiovascular risk”.
The HEART UK Medical, Scientific and Research Committee had 2
meetings regarding the consensus paper. The first meeting critically
reviewed the literature and agreed the ten statements to be included.
The second meeting examined the first draft of the consensus paper. JC
and RDGN compiled the first draft. All committee members contributed
to revision of the manuscript.
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